1. Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study.
- Author
-
Michalowski, Mariana Bohns, Cecconello, Daiane Keller, Lins, Mecneide Mendes, Carvalho, Maria do Perpétuo Socorro Sampaio, Silva, Klerize Anecely de Souza, Cristofani, Lilian, Bonilha, Thais Alcantra, Baglioli, Bianca Faustini, Pianovski, Mara Albonei Dudeque, Kuczynski, Ana Paula, Santiago, Pablo, Rechenmacher, Ciliana, Alegretti, Ana Paula, Rodrigues, Karla, de Magalhães, Mariana Rodrigues, and Daudt, Liane Esteves
- Subjects
LYMPHOCYTIC leukemia ,ACUTE leukemia ,ASPARAGINASE ,CHRONIC leukemia ,PROGNOSIS ,LYMPHOBLASTIC leukemia - Abstract
Summary: Our group recently showed that the (ASNase) formulation available in Brazil from 2017 to 2018 when used at the same dose and frequency as the formulation provided previously did not reach the activity considered therapeutic. Based on these, our goal was to assess the impact of these facts on the prognosis of children with ALL at different oncology centers. A multicentre retrospective observational study followed by a prospective follow‐up. Patients aged >1 and <18 years in first‐line treatment followed up at 10 referral centres, between 2014 and 2018 who received the formulation Leuginase® were identified (Group B). For each patient, the centre registered 2 patients who received ASNase in the presentation of Aginasa® exclusively (Group A). Data collection was registered using (Redcap®). A total of 419 patients were included; 282 in Group A and 137 in B. Group A had a 3‐year OS and EFS of 91·8% and 84·8% respectively, while Group B had a 3‐year OS of 83·8% (P = 0·003) and EFS of 76·1% (P = 0·008). There was an impact on 3‐year OS and EFS of children who received a formulation. This result highlights the importance of evaluating ASNase and monitoring its activity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF